quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:56:43·52d
ANALYSTRating
Novo Nordisk A/S logo

Novo Nordisk A/S downgraded by Goldman with a new price target

NVO· Novo Nordisk A/S
Health Care
Original source

Companies

  • NVO
    Novo Nordisk A/S
    Health Care

Recent analyst ratings

  • Mar 26UpdateWolfe Research-
  • Mar 18UpdateBernstein-
  • Mar 18UpdateBernstein$175.00
  • Mar 10UpdateTD Cowen$42.00
  • Mar 3UpdateMorgan Stanley$40.00
  • Mar 2UpdateGoldman$41.00

Related

  • PR17h
    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
  • SEC3d
    SEC Form 6-K filed by Novo Nordisk A/S
  • SEC3d
    SEC Form 6-K filed by Novo Nordisk A/S
  • SEC10d
    SEC Form 6-K filed by Novo Nordisk A/S
  • SEC16d
    SEC Form 6-K filed by Novo Nordisk A/S
  • SEC24d
    SEC Form 6-K filed by Novo Nordisk A/S
  • SEC27d
    SEC Form 6-K filed by Novo Nordisk A/S
  • SEC27d
    SEC Form 6-K filed by Novo Nordisk A/S
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022